Match!
Glen A. Doherty
University College Dublin
Inflammatory bowel diseaseUlcerative colitisDiabetes mellitusGeneral surgeryMedicine
226Publications
23H-index
2,502Citations
What is this?
Publications 242
Newest
SUMMARY This study reviews the safety and efficacy of treatment with vedolizumab for patients with inflammatory bowel disease across 9 Irish hospitals. It generates valuable and timely real-world data on treatment outcomes to add to the existing evidence base. Our population represents a refractory cohort with most patients previously exposed to at least one anti-TNFa agent and expressing an inflammatory phenotype. Results are reassuringly similar to larger international studies with additional ...
Source
Last. Olivia Mason (UCD: University College Dublin)H-Index: 1
view all 12 authors...
Background/objective Colorectal cancer (CRC) screening is proven to reduce CRC-related mortality. Faecal immunochemical testing (FIT)-positive clients in the Irish National CRC Screening Programme underwent colonoscopy. Round 1 uptake was 40.2%. We sought to identify barriers to participation by assessing knowledge of CRC screening and examining attitudes towards FIT test and colonoscopy. Methods Questionnaires based on a modified Champion’s Health Belief Model were mailed to 3500 invitees: 1000...
Source
#1Fernando Magro (University of Porto)H-Index: 32
#2Glen A. Doherty (UCD: University College Dublin)H-Index: 23
Last. Luc Biedermann (UZH: University of Zurich)H-Index: 19
view all 16 authors...
Currently, the main targets of drug therapy for ulcerative colitis [UC] are endoscopic and clinical remission. However, there is active discussion about the additional advantages of including histological remission as a target. Accumulating evidence indicates that microscopic activity persists in endoscopically quiescent UC, that histological changes may lag behind clinical remission after treatment, and that absence of histological activity predicts lower rates of relapse, hospitalisation, surg...
Source
BACKGROUND: Ustekinumab is effective in Crohn's disease. However, a substantial proportion of patients will not respond or lose response to ustekinumab. The current evidence to support the effectiveness of dose-optimisation for ustekinumab nonresponse is limited. AIM: To assess the effectiveness of dose escalation of ustekinumab. METHODS: This was a multicentre retrospective cohort study. We included active Crohn's disease patients who received a standard-dose intravenous induction and at least ...
Source
Last. A O'TooleH-Index: 6
view all 13 authors...
Source
#1Lisa O’ByrneH-Index: 1
#2Jolene WitherspoonH-Index: 2
Last. Stephen Patchett (Beaumont Hospital)H-Index: 18
view all 26 authors...
Barrett's esophagus (BE) is the main pathological precursor of esophageal adenocarcinoma (EAC). Progression to high-grade dysplasia (HGD) or EAC from nondysplastic BE (NDBE), low-grade dysplasia (LGD) and indefinite for dysplasia (IND) varies widely between population-based studies and specialized centers for many reasons, principally the rigor of the biopsy protocol and the accuracy of pathologic definition. In the Republic of Ireland, a multicenter prospective registry and bioresource (RIBBON)...
Source
#1Joana TorresH-Index: 16
#2Stefanos Bonovas (Humanitas University)H-Index: 30
Last. Gionata Fiorino (Humanitas University)H-Index: 30
view all 46 authors...
This article is the second in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn's disease. The first article covers medical management; the present article addresses surgical management, including preoperative aspects and drug management before surgery. It also provides technical advice for a variety of common clinical situations. Both articles together represent the evidence-based recommendations of ...
25 CitationsSource
#1D. J. Gibson (Alfred Hospital)
#2Glen A. DohertyH-Index: 23
view all 2 authors...
Source
#1Eric J. Brown (UCD: University College Dublin)H-Index: 1
#2C R RowanH-Index: 3
Last. Cormac T. Taylor (UCD: University College Dublin)H-Index: 53
view all 12 authors...
The HIF hydroxylase enzymes (PHD1-3 and FIH) are cellular oxygen-sensors which confer hypoxic-sensitivity upon the hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Microenvironmental hypoxia has a strong influence on the epithelial and immune cell function through HIF-dependent gene expression and consequently impacts upon the course of disease progression in ulcerative colitis (UC), with HIF-1alpha being protective while HIF-2alpha promotes disease. However, little is known about how inflam...
Source
#1J. O'ConnellH-Index: 1
Last. David KevansH-Index: 12
view all 16 authors...
Source
12345678910